Related Experiment Video
Updated: Jun 12, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
[Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta]
1Department of Pediatrics, Osaka Koseinenkin Hospital.
Insights
Osteogenesis imperfecta (OI) is a genetic bone disorder. Bisphosphonates like pamidronate and zolendronate are used for treatment, with newer options showing promise but needing more research on optimal use and long-term safety.
Area of Science:
- Medical Genetics
- Pharmacology
- Orthopedics
Background:
- Osteogenesis imperfecta (OI) is a genetic disorder causing bone fragility and low bone density.
- Current treatments for moderate to severe OI include cyclic intravenous pamidronate.
- Oral bisphosphonates offer benefits and convenience for mild OI cases.
Purpose of the Study:
- To review the current treatment landscape for Osteogenesis Imperfecta.
- To evaluate the efficacy and safety of newer bisphosphonate therapies.
- To identify areas for future research in OI management.
Main Methods:
- Literature review of studies on bisphosphonate treatment for OI.
- Analysis of clinical trial data for intravenous and oral bisphosphonates.
- Comparison of pamidronate and zolendronate efficacy and safety profiles.
Main Results:
- Intravenous pamidronate is the standard for moderate to severe OI.
- Oral bisphosphonates are effective for mild OI.
- Short-term data suggest intravenous zolendronate is safe and effective in children with OI, comparable to pamidronate.
Conclusions:
- Bisphosphonates are crucial in managing Osteogenesis Imperfecta.
- Newer bisphosphonates like zolendronate show potential but require further investigation.
- Optimal dosing, treatment duration, and long-term safety of novel bisphosphonates need extensive study.
Abstract:
Osteogenesis imperfecta (OI) is a genetic disorder characterized by fragile bone and reduced bone mineral density. Cyclic intravenous pamidronate is now the most widely used treatment for moderate to severe forms of OI. Oral bisphosphonates provide clinical benefit and convenience to the patients with mild form of OI. Recently, some studies demonstrated that intravenous zolendronate in children with OI is safe in short-term and similarly effective to parmidronate. Optimal dose, duration of treatment and long-term safety of newer bisphosphonates require further investigations.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
What is the Skeletal System?
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
The Functions of the Skeletal System
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Osteoclasts in Bone Remodeling
